DLI is dramatically effective in inducing sustained remissions and cure in patients with chronic myelogenous leukemia (CML) in chronic phase.

Mar 15, 2024 · Some small studies, particularly in the CML setting have shown efficacy of a lower CD3+ starting dose for initial DLI infusion, which in some ...

Jul 25, 2016 · Our study shows that early administration of G-DLI is feasible after PTCy-based haploidentical hematopoietic stem cell transplantation for refractory/relapsed ...

Our data show that competitive repopulation can be sufficient to reach complete donor-derived hematopoiesis, but that some alloimmunologic pressure is needed.

Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood. 2002;100:397–405. PubMed Web of ...

Our study shows that early administration of G-DLI is feasible after PTCy-based haploidentical hematopoietic stem cell transplantation for refractory/relapsed ...

Donor lymphocyte infusion (DLI) is an important treatment modality in the management of relapsed hematological malignancies after allogeneic hematopoietic ...

The combination of T-cell depleted allograft and post-transplant donor lymphocyte infusion is a viable alternative to the use of unmanipulated donor marrow.

We conducted a study to estimate the maximum tolerated dose (MTD) of 131I– anti-CD45 antibody (Ab; BC8) that can be combined with a standard reduced- ...

Escalating doses of cells were administered in the absence of graft-versus-host disease (GVHD) or continued disease progression, until stable full donor ...